Patient Selection Indications
- Stable or Unstable Angina
- Heart Attack – Acute Myocardial Infarction
- Cardiogenic Shock
- Congestive Heart Failure
- Patients with anginal equivalent symptoms, for example dyspenea or fatigue related to ischemia
- Patients with ischemic Cardiomyopathy including those with EF< 35% that are medically compensated
- The elderly, diabetics and small females
- Those with unsuitable coronary anatomy: small, diffuse and/or distal vessel disease
- Prior failed revascularization
- Renal insufficiency
- Compromised CNS circulation or those receiving steroid therapies
- Patients with moderate to severe angina who cannot tolerate medical therapy
- Patients with Prinzmental Angina class III or IV symptoms despite medical therapy
- Patients whose quality of life is significantly impaired and who have become sedentary due to fear including angina attacks
- Patients taking excessive nitrates
Other Treatable Conditions
The FDA has granted the RejuvaHeart™ protocol clearance for treating a variety of conditions including the following:
- Aortic Insufficiency
- Arrhythmia
- Erectile Dysfunction
- Diabetic
- Fatigue/Malaise
- Heart Failure
- Hepato-Renal Syndrome
- Hypertension
- Peripheral Vascular Disease or Phlebitis
- Restless Leg Syndrome
- Retinal Artery Occlusion
- Rotational Vertebro-Basilar Insufficiency
- Stroke
- Sudden Deafness
- Tinnitus
- Unstable Angina
Contraindications
According to current FDA labeling, RejuvaHeart™ Therapy should not be used for treating patients with:
- Arrhythmias that interfere with machine triggering
- Bleeding diathesis
- Active thrombophlebitis
- Severe lower extremity vaso-occlusive disease
- Presence of a documented aortic aneurysm requiring surgical repair
- Pregnancy
